Phase II Prefusion Non-Stabilized COVID-19 mRNA Vaccine Randomized Study

ChulaCov19 mRNA vaccine demonstrated promising Phase I results. Healthy adults aged 18–59 years were double-blind randomized 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo.